Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets in the negative
Thu, 10 Sep 01:30 pm

Indian Indices continued to trade on a negative note in the post noon trading session. Most sectoral indices are trading on a negative note with stocks from the aluminum and banking sectors leading the losses.

The BSE-Sensex is trading down by 214 points (down 0.8%) and the NSE-Nifty is trading down by 74 points (down 0.9%). The S&P BSE Midcap index and the S&P BSE Smallcap index are also trading in the red, down by 0.1% and 0.8% respectively. Gold prices, per 10 grams, are trading at Rs 26,102 levels. Silver price, per kilogram, is trading at Rs 35,444 levels. Crude oil is trading at Rs 2,947 per barrel. The rupee is trading at 66.47 to the US dollar.

Software stocks are trading on a mixed note with HCL Technologies and Info Edge leading the losses. As per a leading financial daily, Wipro has entered into a partnership with BlackLine Inc, a leader in Enhanced Finance Controls and Automation (EFCA) software. As part of this partnership, Wipro will offer BlackLine's platform of financial software solutions, encompassing Financial Close Management, Intercompany Hub, Reconciliation Management and Controls Assurance delivered as a cloud-based service, to finance and accounting organizations. Further, the company has reported that it will partner with BlackLine in projects and initiatives with the ultimate goal to deliver value to its clients and support them globally. Scrip of Wipro is presently trading down by nearly 1%.

Stocks in the pharmaceutical space are trading mixed with Wockhardt Ltd and Indoco Remedies leading the gains. As per a leading financial daily, Dr. Reddy's Laboratories has entered into a multi-country supply and licensing agreement with PanTheryx Inc., a global medical nutrition company. The agreement grants Dr. Reddy's the exclusive right to market and distribute PanTheryx's breakthrough nutritional intervention, DiaResQ, for infectious diarrhea in India and Nepal. The company is going to market this product under the ‘Reliqua' brand. Stock of Dr. Reddy's Laboratories is presently trading down by 1.7% on the BSE.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets in the negative". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.